In this study we have examined hFcyRl expression during myelopoiesis. Normal bone marrow (BM) cells were found to express hFcyRl up to the metamyelocyte stage. A different FcyRl expression pattern was observed in an in vitro model of myelopoiesis. Purified CD34-positive BM cells, cultured for 1 2 to 14 days with granulocyte colony-stimulating factor (G-CSF), differentiate into a population of mature granulocytic cells. In these cultures, in which hFcyRl was virtually absent on the initial CD34-positive BM cells, hFcyRl was strongly induced by G-CSF after only 5 days. During final maturation the cells remained hFcyRl positive. This expression was confirmed functionally by antibodysensitized erythrocytes (EA)-rosette assays. Moreover, the mature myeloid cells were found to express mRNA encoding for hFcyRI, whereas reverse-transcriptase polymerase chain reaction analysis showed that both hFcyRlA and hFcyRlB genes were expressed. In contrast, on peripheral N BLOOD CELLS, a heterogeneous group of receptors 0 have the capacity to bind the Fc region of IgG. These receptors, collectively called Fcy receptors, provide an important bridge between the humoral and cellular branches of the immune Three classes of Fcy receptors can be distinguished, hFcyRI (CD64), hFcyRII (CD32), and hFcyRIII (CD16), respectively. Each class of receptors consists of closely related molecules encoded by different genes: hFcyRIA, B, and C, hFcyRIIA, B, and C, and hFcyRIIIA and B. The expression of these three classes of surface molecules on peripheral blood leukocytes has been studied extensively. In the peripheral blood, hFcyRII and hFcyRIII are widely distributed: hFcyRII can be detected on monocytes, neutrophils, eosinophils, basophils, B cells, and platelets, whereas hFcyRIII is found on neutrophils and natural killer cells.'X2 In the peripheral blood, hFcyRI is expressed exclusively on monocytes, whereas neutrophils can be induced to express this receptor by interferon gamma (IFN-y), both in vitro3-' and in vivo.' Data on hFcyRI expression patterns during myelopoiesis are limited. Progressive loss of the highaffinity Fcy receptor during myeloid differentiation has been reported." By means of cell sorting experiments of bone marrow (BM) cells, Ball et all' showed that significant percentages of the committed myeloid progenitors (colonyforming unit granulocyte-macrophage) express hFcy RI and hFcyRII (20% and 66%, respectively). Moreover, granulocytic precursors up to the level of band forms were found to express hFcyRI. Interestingly, Repp et all2 reported the occurrence of hFcyRI expressing granulocytes after in vivo application of granulocyte colony-stimulating factor (G-CSF), a finding that could not be explained by an in vitro effect of G-CSF on circulating granulocytes.
In this report, we studied in detail the hFcyRI expression pattern during myeloid differentiation. Using an in vitro model,13 in which purified CD34+ BM cellsk4 are cultured in the presence of G-CSF, we assessed expression of Fcy receptors by means of immuno-flow cytometry. Furthermore, in this system we analyzed the regulation of hFcyRI expression, blood (PB) polymorphonuclear neutrophil leukocytes (PMN) the in vitro effect of G-CSF as to hFcyRl induction was limited. Therefore, we conclude that, with respect to hFcyRl expression on PMN, G-CSF acts on myeloid precursor cells rather than on mature cells. This conclusion could be strengthened by in vivo administration of a single dose of G-CSF to a healthy volunteer. After a 12-hour lag time, hFcyRl expressing PMNs were detected in the peripheral blood. This study shows that hFcyRl is an early myeloid differentiation marker that is lost during normal final maturation. However, committed myeloid progenitor cells can be strongly induced by G-CSF to express hFcyRI, ultimately resulting in mature granulocytic cells expressing the highaffinity receptor for IgG. This expression may have important consequences for the functional capacity of these cells. using EA-rosette assays, northern blotting, and polymerase chain reaction (PCR) analysis. For comparison, we analyzed the morphology of hFcyRI-expressing cells in freshly isolated normal BM. Finally, the effect of G-CSF on hFcyRI expression on peripheral blood polymorphonuclear neutrophil leukocytes (PMN) was investigated both in vitro as well as on in vivo administration of a single dose of G-CSF to a healthy volunteer. Our data support the concept that the G-CSFinduced expression of hFcyRI on PMN is the result of G-CSF action on myeloid precursor cells.
MATERIALS AND METHODS
Preparation of BM cells and CD34-enriched progenitor cells. BM cells were aspirated from patients undergoing cardiac surgery (Dr Eijsman; Dept of Cardiac Surgery, Academic Medical Center, Amsterdam, The Netherlands) and from hematologic patients in complete remission whose disease did not involve the myeloid lineage (no differences in growth rate and differentiation were observed between BM from these two patients groups). Informed consent was obtained according to the rules of our hospital. To enrich for CD3Cpositive cells, mononuclear cells were isolated by density gradient centrifugation (Ficoll-Paque; Pharmacia, Uppsala, Sweden; d = 1.077 g/mL). CD2-, CD19-, and CD67-positive cells were depleted by immuno-rosettes and density centrifugation as described. 15 The enriched cells were then labeled with fluorescein isothiocyanate (FITC) conjugated MoAb 8G12 (CD34) and purified by cell sorting (FACStar, Becton & Dickinson, San Jose, CA). The final cell populations contained 95% to 99% CD34+ cells as determined by flow cytometry.
Morphologic analysis of hFqI2I-expressing cells in BM. Normal erythrocytedepleted unfractionated BM samples were separated into hFcyRI-positive and -negative fractions by cell sorting (FACStar). The fractions were then cytocentrifuged, stained with Jenner-Giemsa according to standard techniques, and scored microscopically. To determine the proportion of hFcyR1-positive and -negative cells at each differentiation stage, the following calculations were performed the percentage of each cell type in the positive and negative cell fractions was multiplied by the number sorted into that fraction to obtain absolute cell numbers. The proportions of the specific cell types present in each of the fractions could then be calculated.
Five thousand purified CD34+ cells were plated per 35-mm Petri dish in 1 mL culture medium consisting of Iscove's modified Dulbecco's medium (IMDM) supplemented with 20% (vol/vol) fetal bovine serum, 2 mercapto ethanol (0.1 mmol/L), penicillin (100 lU/mL), streptomycin (100 pg/mL), bovine serum albumin (BSA; 0.83%, wt/vol), transferrin (0.77 mg/mL), and glutathione (0.08 mg/mL). Recombinant human G-CSF (Amgen, Thousand Oaks, CA; 20 ng/mL) or human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF; Sandoz, Uden, The Netherlands: 20 ng/mL) were added at day 0.
After different culture periods at 37°C and 5% COz, cells were collected for immunophenotypical, cytologic, functional, and biochemical analyses.
Blood was obtained from healthy volunteers (500 mL blood anticoagulated with 0.4% [wt/vol] trisodium citrate, pH 7.4), and PMN were carefully purified from buffy coats as described. 16 On isolation, cells were suspended in IMDM supplemented with 10% (vol/vol) fetal bovine serum, penicillin (100 IU/mL), and streptomycin (100 pg/mL) at a concentration of 2 x Io6 cells/mL and cultured for 12 to 16 hours (37"C, 5% COz) in suspension in 96-well flat-bottomed plates (Nunclon, Roskilde, Denmark; precoated with 0.5% human serum albumin [CLB] for 1 hour at 37°C). Recombinant human GM-CSF (20 ng/mL), recombinant human G-CSF (20 ng/mL), or IFN-y (Boehringer Ingelheim, Mannheim, Germany; 100 U/mL, specific activity: 2 X lo7 U/mg) were added at the onset of cultures. On culture, cells were harvested and hFcrR1 expression was analyzed by immuno-flow cytometry.
Immunophenotypical analysis. Fcy receptor expression on CD34' BM cells at the onset of culture was evaluated as follows: the BM mononuclear cells were first incubated with a panel of MoAbs. Subsequently, cells were stained with phycoerythrin-labeled rat-antimouse antibody (Becton Dickinson). The residual binding sites of the latter antibody were blocked with a mixture of irrelevant murine antibodies of mlgG1 and mIgG2a isotypes. The CD34 antigen was detected by FITC-labeled 8G I2 MoAb.
Antigen expression of progenitor cells cultured in suspensions was analyzed by indirect immuno-fluorescence according to standard techniques, using a panel of murine MoAbs against monomyeloid antigens. The following antibodies were used: CLB-HLA-class I1 (HLA-DR), CLB-gran/2 (CD15), B 13. Total cellular RNA was isolated from the erythroid cell line K562 and from the CD34+ BM cells directly on isolation, following culture with G-CSF for 11 days, using the RNA zol B method (Cinna Biotecx, Friendswood, TX).27 Ten micrograms of RNA was then fractionated by electrophoresis, in 1% agarose/ formaldehyde gels, and transferred to nitrocellulose (BA85; Schleicher and Schuell, Dassel, Germany). Hybridization with hFcyR cDNA probes was performed ovemight in 50% formamide, 3X SSC, 0.1% sodium dodecyl sulfate (SDS), IOX Denhardt's solution, supplemented with 50 pg/mL denatured salmon sperm DNA at 42°C. Filters were washed in 0.3X SSC, 0. I% SDS at 42°C for 30 minutes. A 1.4-kb Xho I fragment of cDNA ~1 3 5 ,~' a 700-bp Pst I fragment of cDNA P P W~?~ and a 900-bp HindIlI/EcoRI fragment of cDNA F~y R l 1 I -l~~ were used to probe hFcyRI, hFcyRlI, and hFcyRIII, respectively. Probes were labeled with [ ( U -~~P I~C T P using a random primer labeling kit (BRL, Bethesda, MD).
Quantitation of hFcyRI transcripts by reverse transcriptase polymerase chain reaction (RT-PCR). Five micrograms of total RNA, isolated as described above, was reverse transcribed to cDNA using Avian Moloney virus reverse transcriptase (1 7 U; Pharmacia) for 90 minutes at 42°C. Incubations were in a total volume of 50 pL, containing 10 mmol/L MgCI2, 100 mmol/L Tris-HCI (pH 8.3), 140 mmol/L KCI, 2 mmol/L DTT, 0.2 mmol/L of each dNTP, and 100 ng of NotI-d(T),* primer (Pharmacia). In most cases, RT reactions were used directly for PCR amplification, or otherwise stored at -20°C. Three microliters of RT-cDNA was added to a PCR reaction (100 pL final volume), which contained 1 X PCR buffer (Promega, Madison, Wl), 0.25 mmol/L each of four dNTP, I O pmol of each oligonucleotide primer, and 1 U Taq DNA polymerase (PerkinElmer).
Two primers were used to amplify hFcrRI transcripts, primer 9 (5'-ACACCACAAAGGCAGTGA-3' ) corresponding to nucleotides 89-106, and primer IO (5'-CACCCAGAGAACAGTGTT-3') corresponding to the reverse complement of nucleotides 952-969 of cDNA ~1 3 5 .~' Human actin RT-cDNA was amplified by using primer "5' actin" (5'-GGCGACGAGGCCCAGAGCAAGAGAGAG-3') corresponding to nucleotides 204-228, and primer "3' actin" (5'-TGC-CCAGGAAGGAAGGCTGGAAGAG-3' ), corresponding to the reverse complement of nucleotides 822-846 of human p actin CDNA.'~ PCR cycles were performed in an automated DNA thermal cycler (Bio Phase; Bio Excellence, Colchester, UK) using the following temperature profile; denaturation at 94°C for 2 minutes, primer annealing at 55°C for 2 minutes, and primer extension at 72°C for 3 minutes. To quantitate the relative amounts of hFcyRl and actin RT-cDNA in the different samples, 22.5 pL of the PCR products were removed after 15, 20, 25, and 30 cycles. Ten microliters of each sample were then fractionated by agarose gel electrophoresis and visualized by
Northern blot analysis.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From ethidium bromide staining (see Fig 5A and B) . PCR products were then blotted to nitrocellulose, and specific hFcyRIa and Ib PCRproducts were detected by hybridization with gene-specific oligonucleotides 37A (5'-GAATATCTGTCACTGTGA-3' ) and 39B (5'-GAATATCACAATACACTG-3' ).'I Oligonucleotides were S-phosphorylated with [y12P] adenosine triphosphate (ATP) and polynucleotide kinase (Pharmacia). Actin PCR-product was detected by I2P-labeled, 700-bp EcoRV fragment of human 0 actin cDNA." Relative amounts of hFcyRIa (present in 880-bp PCR band"), hFcyRlb2 (present in 600-bp PCR band"), and actin (in the 642-bp PCR product) were quantitated by measuring their incorporated radioactivity on blots with a Molecular Dynamics 400A Phosphor-imager System (Molecular Dynamics, Sunnyvale, CA). In some PCR experiments we observed a third band (~7 5 0 bp) at high cycle numbers (>30) in the hFcyRI-PCR (eg, see Fig 5A) , which did not represent a true transcript and did not affect quantitation of hFcyRla and Ib2 transcripts (at low cycle numbers). To correctly compare the relative amounts of hFcyR1 and actin RT-cDNAs in the different samples, only samples present within the range of exponential amplification were used for quantitation."
A single dose of G-CSF (Neupogen, Amgen, 300 pg subcutaneously) was administered to a healthy volunteer (informed consent was obtained according to the rules of our hospital). Subsequently, at different time points blood was collected in EDTA for immediate anticoagulation. For erythrocyte lysis, cells were incubated for 10 minutes with ice-cold isotonic NH4CI solution (155 mmol/L NH4CI, 10 mmol/L KHC03, 0.1 mmol/L EDTA, pH 7.4), centrifuged in the cold, and the residual erythrocytes were lysed during 3 minutes more. The remaining cells were washed twice in cold PBS/BSA 0.2% (wt/vol) and analyzed by immuno-flow cytometry.
Student's t-tests were performed for paired differences.
In vivo administration of G-CSF.
Statistical ana/.vsis.
RESULTS
Morphologic anal-vsis of hFc/RI-expressing cells in normal BM. Freshly isolated normal BM cells were separated into hFcyRI-positive and -negative cells by cell sorting and the morphology was determined subsequently. In bone marrow from three individuals, 24.4% k 2.5% of unfractionated BM cells were hFcyRl positive. Blast cells were detected exclusively in the hFcyRI-negative cell fraction (Fig I) . Cells of intermediate differentiation stages were found to be equally distributed over the two cell fractions. On maturation into bands and polymorphonuclears, hFcy RI expression diminished strongly. Lymphocytes were detected in the hFcyRInegative cell fraction, whereas most monocytes were hFcyRl positive.
The expression of hFcrRI on in vitro generated mature granulocytic cells. As reported," culturing of CD34' BM cells for 12 to 14 days in the presence of G-CSF results in a population in which the majority of cells consists of mature granulocytic cells. This is evident both from morphology (differential counts: myelocytes 4% f I%, metamyelocytes 11% k 4%, band forms 47% k 6%, and segmented cells 38% f 4%, mean f SEM; n = 4), and immunophenotype (CD15, 75.4% f 0.6%; CD67,70.7% f 2.0%). Interestingly, as shown in Fig 2, high percentages of these mature day 14 cells were found to express hFcyRI (63.9% f 3.8%; corrected mean fluorescence intensity [MFI] 47.5 f 5.3). Both hFcyRII and hFcyRlll were expressed on 54.4% f 10.6% and 20.5% k 4.2% of the cells, respectively (MR 52.7 ? 13.4 and 17.9 f 7.9). To study the expression of hFcyRI functionally. we assessed the ability of the cultured cells to bind mlgG2a-coated human erythrocytes (EA-mIgG2a rosettes) and antiRhesus D-sensitized erythrocytes. Previous studies have shown that the murine isotype mlgG2a interacts strongly with h F~y R 1 ,~~ whereas Rhesus D-sensitized erythrocytes are established indicator cells for the high-affinity IgG Fcy receptor.*' It was found that 72% f 5% of the day 14 cells formed mIgG2a EA-rosettes (Fig 3) and 68% f 5% formed EA-Rh D rosettes (n = 5). The specificity of mlgG2a for hFcyRI has been established in T-cell proliferation studies, EA-rosetting, modulation studies, and antibody-dependent cellular cytotoxicity.' Inhibition analyses with CD64 MoAb 197 provided additional proof that hFcyRl mediates rosetting between cultured BM cells and EA-mIgG2a (inhibition: 97.5% f 0.9%, n = 3). A combination of blocking CD32 (IV.3, mlgG2b) and CD16 (3G8, mlgGI) MoAbs had only a marginal effect on EA-mlgG2a rosetting (3.2% & 1.5% inhibition, n = 3). As shown in Fig 4A, mRNA for hFcyRl was abundantly present in these mature cells. Furthermore, RT-PCR analysis demonstrated that the cells expressed both hFcyRla and hFcyRIb genes (Fig 5A) . The relative abundance of the two transmembrane forms of hFcyRI, la and Ib23' was quantitated by using the ubiquitously expressed actin (Fig 5B) to serve as an internal control for the amount of RNA tested (semiquantitative PCR). In all three donors,
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culture of CD34+ BM cells unequivocally led to a strong enhancement of both hFcyRIa and Ib2 transcripts (Fig 5C) . The cells generated in vitro also transcribed hFcyRIl and hFcyRllI genes (Fig 4C and D) , although hFcyRIll mRNA was expressed relatively weakly. The hFcyRIl expressed on these cells was found to be a product of the hFcyRIlA gene, as was demonstrated by a polymorphic reactivity with mIgG I:' evaluated in rosetting experiments with EA-mIgGI. It was observed that G-CSF stimulated CD34+ BM cells from some donors effectively formed rosettes (48% & 5%, n = 5) with EA-mlgG I (high responders). Cells from the remaining individuals (low responders) did so only weakly (4% & 2%, n = 3). EA-mlgG 1 rosettes could be blocked completely with F(ab')* fragments of CD32 MoAb ATIO. Staining patterns with 41H 16 (an MoAb that has a unique specificity for the HR allelic form of hFcyRIIa'') and IV.3 (recognizing both allelic forms of hFcyRlla) MoAbs were always found consistent with the EA-mlgG I rosette experiments.
Kinetics of hFcyRI expression during in vitro myelopoiesis. To study the kinetics of hFcyRl expression on CD34+ cells during culture with G-CSF, cells were harvested at different time intervals and analyzed for hFcyRl expression immunophenotypically and functionally. Immunophenotypically, at day 0 the expression of hFcyRl (CD64) and hFcyRIl (CD32) on CD34' BM cells was very low, albeit significantly higher than the controls (6.8% k 2.2% and 9.5% & 3.1% positive cells). The hFcyRIII (CD16) was undetectable on the progenitor cells (Fig 2) . However, at the onset of culture, no rosette formation was observed between CD34' BM cells and EA-mlgG2a (Fig 3) . In accordance. by Northern blot analysis no mRNA for any of the hFcy receptors was -1 1, 6-11, C-11 8 ' 1 Relative Abundance of PCR-products 4 J r detectable in the initial cell populations (Fig 4) . As reported before," G-CSF induces a sharp increase in proliferation of CD34+ cells until day 11, after which proliferation declines. Immunophenotypically, cells cultured with G-CSF downregulate HLA-DR (day 0, 85.6% ? 4.8%; day 14, 10.3% ? 2.0%), whereas subsequently, mature granulocytic antigens CD I5 and CD67 are upregulated. At day 5 of culture, significant numbers of the cells express CD15 (39.2% ? 2.6%); a strong induction of CD67 can be observed from day 9 onward (37.9% ? 6.8%). Figure 2 shows the sequence of the expression of Fcy receptors during this G-CSF-induced in vitro differentiation of CD34+ cells. The first FcyR to be expressed was hFcyRI (at day 5 already 31.3% f 4.9%, reaching levels of 52.8% f 3.4% at day 9 and 63.9% ? 3.8% at day 14). The hFcyRll appeared somewhat later: at day 5, only 8.7% f 4.2% of the cells expressed hFcyRII, reaching a level of 54.4% f 10.6% at day 15. The hFcyRIll was only expressed on low numbers of cells (day 5,0.8% ? 0.3%; day 15, 20.5% f 4.2%). Soluble hFcyRIII could not be detected in the culture supernatant using a very sensitive radioimmunoa~say~~ (data not shown). Functional analysis of hFcyRI expression during in vitro maturation showed a strong increase of EA-mIgG2a rosetteforming cells from day 5 or 6 onward (25. 7% ? 4.4%, Fig 3) , reaching levels comparable to the percentage of positive cells as determined by immunoflow cytometry with CD64 MoAb. Next, the effects of G-CSF were compared with granulocytemacrophage (GM)-CSF. Although GM-CSF also induced an initial hFcyRI expression, by day 5 or 6 the expression had 
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reached a plateau of 20% to 30%. In the presence of a combination of GM-CSF and G-CSF, the cells formed EAmlgG2a rosettes more rapidly, but the rosetting pattern was similar to that in cultures with G-CSF alone.
To exclude the premise that IFN-y, a known potent inducer of hFcyRl on both monocytes and PMN,' mediates the effects on hFcyRI during culture of CD34+ BM cells, we performed control CD34+ BM cultures in the presence of neutralizing antibodies against IFN-y (final concentration 5 pg/mL; neutralizing 900 U/ mL IFN-yZ4) . No effect on G-CSF-induced hFcyRI expression was observed (percentage inhibition in two experiments; 3.5% and 5.4%, respectively). Moreover, in agreement with Zoumbos et al,37 addition of exogenous IFNy to cultures strongly inhibited proliferation of G-CSF-cultured CD34' BM cells (data not shown).
In vitro effeccr ofG-CSF on hFcyRI expression by peripheral blood (PB) PMN. Purified, freshly isolated PB PMN were cultured for 12 to 16 hours in the presence of either GM-CSF, G-CSF, or IFN-y (Fig 6) . GM-CSF did not affect the expression of hFcyRI (MFI, 2.3 ? 0.9; 3.5% ? 1.2% positive cells). Compared with PMN cultured in medium alone, a moderate albeit significant (P < .05) hFcyRI expression was observed in response to culture with G-CSF (MFI, 6.7 ? 2.8; 23. I% f 7.8%). IFN-y induced a marked upregulation (P e .002) of hFcyRI expression (MFI, 14.2 f 2.5; 30.7% f 4.2%).
The expression of hFcyRI on PB PMN on G-CSF administration in vivo. G-CSF (neupogen; 300 pg subcutaneously) was administered to a healthy volunteer. Figure 7 shows the hFcyRI expression level on PMN at different time intervals after G-CSF administration. Until 12 hours had elapsed, only minimal hFcyRI expression could be detected on PMN. However, between 12 and 72 hours hFcyRI expression was strongly increased. After 24 and 48 hours as much as 77% of the PMNs were hFcyRI positive. Morphologic analysis demonstrated that always more than 90% of the circulating granulocytic cells were polymorphonuclears. After 24 hours these circulating PMN also expressed mRNA coding for hFcyRL3*
DISCUSSION
In this study we have examined hFcyRI expression during myelopoiesis. It was found that ex vivo isolated BM cells express hFcyRI up to the metamyelocytic stage of differentiation. However, during in vitro myelopoiesis, in which CD34+ BM cells cultured in the presence of G-CSF differentiate into a population of mature granulocytic cells,I3 high percentages of these mature cells were found to express hFcyRI, both immunophenotypically and functionally. Moreover, the mature cells expressed hFcyRI mRNA. Recently, three genes have been described encoding ~F c~R I .~' ,~~ RT-PCR analysis showed that hFcyRI mRNA expressed by the cultured cells represented transcripts of both the hFcyRIA gene (encoding hFcyRIa, a transmembrane protein with three extracellular Ig-like domains) and the hFcyRIB gene (hFcyRI2, an alternative splice form that encodes a transmembrane protein with two extracellular Ig-like domains3'). In addition, the mature cells were demonstrated to contain hFcyRII and hFcyIII transcripts. The hFcyRII expressed by the cells was encoded by the hFcyRIIA gene, as was supported by both the polymorphic binding-pattern of EA-mIgG 1 and the differential staining with 4 1 H 16 MoAb, which selectively interacts with the hFcyRIIaHR allotype. 20 The presence of the hFcyRIIa HR-LR polymorphism on mature granulocytic cells derived from CD34+ BM cells cultured with G-CSF is consistent with studies on PB PMN.20,40 Remarkably, only a low percentage of the final mature cell population expressed hFcyRIII. It has been shown that hFcyRIII is easily shed from PMN!' However, soluble hFcyRIII could not be detected in the culture supernatant using a very sensitive radioimmun~assay.~~ Moreover, hFcy RIII mRNA expression was relatively weak compared with hFcyRI and hFcyRII.
Furthermore, we assessed the kinetics of Fcy receptor expression during myelopoiesis in vitro. Immunophenotypically, hFcyRI and hFcyRII expression on the initial CD34+ BM cells was low, whereas hFcyRIII was undetectable. Both functionally and at the level of mRNA, CD34" BM cells did not express hFcyRI. Culturing with G-CSF resulted in a sequential pattern of Fcy receptor expression on CD34' BM cells; first hFcyRI, followed by hFcyRII and hFcyRIII, respectively. The presence of hFcyRI was confirmed functionally by using both mIgG2a and Rhesus D-sensitized erythrocytes. EA-mIgG2a rosette analysis of the BM cells cultured with GM-CSF showed limited hFcyRI expression, consistent with minimal final maturation observed with this cytokine (mainly myelocytes and metamyelocytes"). On culture with a combination of GM-CSF and G-CSF ultimately resulting in metamyelocytes and band forms,'3 hFcyRI expression, although appearing earlier in culture, was essentially the same as with G-CSF alone.
In conclusion, during normal myelopoiesis hFcyRI expression is found until the metamyelocytic stage. This is in agreement with findings by Ball et al." However, during G-CSF-induced in vitro myeloid differentiation, the highaffinity receptor remains expressed during final maturation. We hypothesize that G-CSF acts at the level of precursor cells rather than on mature cells, because we and other investigator^^,^ observed that in vitro G-CSF has only a marginal effect on hFcyRI expression by PMN from PB. Our data may also provide an explanation for recent observations by Repp et all2 who reported hFcyRI expression by neutrophils on in vivo application of G-CSF. To test this hypothesis, we monitored the effect of G-CSF as to hFcyRI expression on PMN in vivo. In the study of Repp et a1," PMN of car- cinoma patients were evaluated 3 days after the start of continuous G-CSF therapy. We now studied the time course of FcRI expression after administration of a single dose G-CSF (300 pg, subcutaneously) to a healthy volunteer. PMN expressing hFcyRI began to appear in the PB no sooner than 12 hours after administration, and maximal hFcyRI expression was observed after 24 hours. This lag-time is consistent with the in vitro findings that G-CSF does not induce hFcRI expression on mature granulocytes, which have a peripheral half-life of only 7 to 8 hours, an interval that has been shown not to be affected by G-CSF!2 Morphologic analysis of circulating cells in the volunteer tested showed more than 90% of the PB granulocytic cells to be polymorphonuclear. Because BM PMN were found to be hFcyRI negative (Fig I) , the release of storage pool granulocytes is unlikely to be responsible for the observed hFcyRI expression on PMN. Thus, our results support the hypothesis that myeloid precursors are the target cells and are in agreement with the observation that G-CSF reduces marrow transit time of the maturating myeloid population (1 day as compared with 4 to 5 days).42 Interestingly, hFcyRIII expression on PMN was found to be strongly decreased on in vivo application of G-CSF. 43 Also, during in vitro maturation we observed only low percentages of the mature cells expressing hFcyRIII. Decreased expression of this PMN surface marker on G-CSF treatment of severe congenital neutropenia patients has been reported previIn our opinion, hFcyRI represents an early myeloid differentiation antigen that is lost during normal final maturation. On in vivo application of G-CSF, hFcyRI remains present during the terminal differentiation process toward mature circulating PMNs. This may also account for the observed presence of hFcyRI on PMN in patients with streptococcal pharyngitis45 because increased levels of G-CSF have been found during bacterial infections!6 The biological significance of the remarkable transient hFcyRI expression during intermediate differentiation stages remains to be elucidated. Interestingly, transient Fcy receptor (I1 and 111) expression has been reported during thymocyte differentiat i on!'
The expression of hFcyRI has been reported to trigger multiple biological functions. ' In vivo administration of G-CSF can activate effector functions in mature PMN.48 Thus, the G-CSF-induced abundant expression of high-affinity receptors for IgG on PMN may possibly provide these cells with an optimal capacity to perform all known functions mediated by Fc receptors.'~~~ ously. 44 
